Compare Moody's Corporation (MCO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Moderna, Inc. — how do they compare? Moody's Corporation trades at $464.23 (market cap $79.44B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moody's Corporation and Moderna, Inc. are close in size by market cap, and Moody's Corporation pays a 0.9% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Moderna, Inc. for 59 Days on average.
| MCO | MRNA | |
|---|---|---|
Market Cap | $79.44B | $78.65B |
Volume | 526,684 | 37,373,437 |
Sector | Financials | Health |
52-Week High | $539.61 | $203.46 |
52-Week Low | $412.23 | $22.36 |
Typical Hold Time | 132 Days | 59 Days |
Enterprise Value | $85.46B | $74.80B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $464.23, up 3.25% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 34.25% net margins and 80.15% ROE. Recent developments include a minority stake acquisition in PhilRatings and continued leadership in risk analytics, supported by 56% analyst buy ratings and a $536.40 consensus target.
Outlook remains positive given consistent revenue growth and expanding profitability, though technical resistance near $464 and high valuation multiples pose near-term risks. Long-term investors may find value in MCO's market position and dividend yield, but should monitor debt levels and macroeconomic sensitivity.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
